Lindsay Lambert
About Lindsay Lambert
Lindsay Lambert is the Director of Clinical Operations at FidoCure®, specializing in veterinary oncology and precision medicine for canine cancers.
Director of Clinical Operations
Lindsay Lambert serves as the Director of Clinical Operations at FidoCure®. In this role, Lambert collaborates with veterinarians to treat canine cancers using targeted therapies. She plays a significant part in facilitating the use of precision medicine, thereby enhancing treatment outcomes for pet dogs battling various types of cancer.
Background in Veterinary Oncology
Lindsay Lambert has a background in veterinary oncology, which equips her with the expertise necessary for her role at FidoCure®. Her specialized knowledge in this field is instrumental in identifying effective treatment pathways for canine cancer patients. This background enables her to work closely with veterinary professionals in applying precision medicine for optimal patient care.
Contributions to Precision Medicine
Lindsay Lambert is actively involved in initiatives that apply precision medicine in veterinary oncology. At FidoCure®, she helps provide DNA testing to identify genetic markers present in each case of canine cancer. Lambert's work has contributed to the collection of 1.7 billion data points on canine cancer and supports treating nearly 5,000 pet dogs.
Collaborating with Veterinarians
In her role, Lindsay Lambert works closely with veterinarians across different states to treat various types of canine cancers, including hemangiosarcoma, bladder cancer, and rare forms such as histiocytic sarcoma. Her efforts are focused on expanding the reach of FidoCure® by building strong relationships with veterinary professionals, thereby enabling access to targeted therapies for a broader canine population.
Research and Peer-Reviewed Publications
Lindsay Lambert has participated in the publication of three peer-reviewed papers that demonstrate the impact of precision medicine on patient outcomes. Her involvement in clinical operations and research at FidoCure® underscores her commitment to advancing veterinary oncology and contributing valuable insights to the scientific community.